|
Rivera-Caravaca JM, Marin F, Vilchez JA, Galvez J, Esteve-Pastor MA, Vicente V, Lip GYH, Roldan V. Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. Stroke. 2019 Jun;50(6):1372-1379. doi: 10.1161/STROKEAHA.118.024305. Epub 2019 May 14. PubMed PMID: 31084333.
AÑO: 2019; IF: 10.17
|
31084333
|
Orenes-Pinero E, Esteve-Pastor MA, Ruiz-Nodar JM, Quintana-Giner M, Veliz-Martinez A, Tello-Montoliu A, Macias-Villanego MJ, Pernias-Escrig V, Vicente-Ibarra N, Carrillo-Aleman L, Sandin-Rollan M, Martinez J, Lozano T, Rivera-Caravaca JM, Marin F. Under-prescription of novel antiplatelet drugs in patients with acute coronary syndrome and previous cardiovascular disease. Minerva Med. 2019 Oct;110(5):410-418. doi: 10.23736/S0026-4806.19.05859-2. Epub 2019 May 6. PubMed PMID: 31081301.
AÑO: 2019; IF: 3.031
|
|
Esteve-Pastor MA, Roldan V, Rivera-Caravaca JM, Ramirez-Macias I, Lip GYH, Marin F. The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. Thromb Haemost. 2019 Dec;119(12):1901-1919. doi: 10.1055/s-0039-1696955. Epub 2019 Sep 9. PubMed PMID: 31499565.
AÑO: 2019; IF: 4.385
|
|
Hernandez-Romero D, Sanchez-Quinones J, Vilchez JA, Rivera-Caravaca JM, de la Morena G, Lip GYH, Climent V, Marin F. Galectin-3 and beta-trace protein concentrations are higher in clinically unaffected patients with Fabry disease. Sci Rep. 2019 Apr 17;9(1):6235. doi: 10.1038/s41598-019-42727-4. PubMed PMID: 30996283; PubMed Central PMCID: PMC6470309.
AÑO: 2019; IF: 3.998
|
|
Rivera-Caravaca JM, Marin F, Esteve-Pastor MA, Galvez J, Lip GYH, Vicente V, Roldan V. Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. BMJ Open. 2019 Dec 15;9(12):e033712. doi: 10.1136/bmjopen-2019-033712. Erratum In: BMJ Open. 2022 Dec 22;12(12):e033712corr1. PubMed PMID: 31843852; PubMed Central PMCID: PMC6924708.
AÑO: 2019; IF: 3.006
|